Transcutaneous CO2 Measurement - From Hospital to Home

University of Oslo1 site in 1 country129 target enrollmentJanuary 1, 2020

ConditionsType 2 Respiratory Failure Hypercapnic Respiratory Failure

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Type 2 Respiratory Failure
Sponsor: University of Oslo
Enrollment: 129
Locations: 1
Primary Endpoint: Success rate home vs hospital
Status: Completed
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Long-term non-invasive ventilation (LT-NIV) is the main treatment modality for chronic hypercapnic respiratory failure.To assess the adequacy of alveolar ventilation during sleep and potential sleep hypoventilation, nocturnal transcutaneous CO2 (PtcCO2) monitoring is necessary. There is an increased tendency to monitor patients at home, but there is a lack of robust data comparing the technical success rates between the home and inpatient setting of PtcCO2 monitoring. The primary aim of the current study was to evaluate the rate of successful nocturnal PtcCO2 monitoring in a home setting in a population of patients with chronic hypercapnic respiratory failure receiving LT-NIV. The secondary aim was to compare these data with PtcCO2 registrations performed during regular follow up of a similar population of patients in a hospital setting.

Detailed Description

Patients scheduled for LT-NIV follow-up at Oslo University Hospital, Ullevål in the time-period January 2020 to December 2022 were prospectively identified. Follow-up monitoring occurred either at home or in the hospital. Two physicians blinded to the location of the monitoring, retrospectively classified the PtcCO2 as successful or unsuccessful, and identified the causes of failure for the latter.

Registry

clinicaltrials.gov

Start Date

January 1, 2020

End Date

December 31, 2022

Last Updated

last year

Study Type

Observational

Sex

All